Lundbeck
44.14
DKK
+2.08 %
HLUN B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
5 following
+2.08%
-2.3%
-8.04%
+19.17%
+34.74%
+33.51%
+36.23%
-14.66%
+79.43%
www.lundbeck.com/global
Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.
Revenue
19.91B
EBIT %
16.05 %
P/E
19.11
Dividend yield-%
1.59 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
HLUN B
Daily low / high price
43.04 / 44.14
DKK
Market cap
43.95B DKK
Turnover
17.98M DKK
Volume
410K
Financial calendar
Annual report
05.02.2025
General meeting
26.03.2025
Interim report
14.05.2025
Interim report
20.08.2025
Interim report
12.11.2025
ShowingAll content types
H. Lundbeck A/S: Lundbeck completes acquisition of Longboard
H. Lundbeck A/S: Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools